© 2020 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Strategy
Critical Connection: Patient Services and Product Launch
October 14, 2020
A look at best-practice approaches to aligning the strategy and design of hub service models with preparations for market entry of a new therapy.
Mastering the Transition From Academia to Industry
October 14, 2020
Tips for rounding out the rough edges in crossover.
Injecting Traditional Scientific Exchange with New Life
October 13, 2020
Female medical affairs leaders speak out with unique perspectives on how MSLs can provide greater value to opinion leaders.
Commercial Sustainability of Pharmaceutical Innovations for Pandemics
September 30, 2020
Assessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.
Best Practices for Balancing Medical Affairs Globalization with Local Requirements
September 29, 2020
Addressing the challenges faced by Global Medical Affairs teams and how they can find balance to create maximum value for their organizations.
Manage Risk Effectively to Improve the Value of Your Alliance
September 29, 2020
In this article, Eli Lilly & Co. examines risk management in the context of partnerships with other companies.
Planning Ahead for a Post COVID-19 Workforce and Workplace
September 20, 2020
Dr. George Westerman talks to Michael Wong about how smarter executives will successfully lead their workforces in a post COVID-19 business environment.
Drug Launch: Winning the Evidence Battle
September 14, 2020
Beyond necessity and nice-to-have, embracing real-world evidence as a true strategic differentiator.
New Standards for First-to-Launch Players
September 14, 2020
While COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.
(O)mega Opportunity: Vascepa
September 14, 2020
Uncovering fish oil derivative’s benefit for heart health.
Educational Mission: Oxbryta
September 14, 2020
New hope accompanies overdue recognition in sickle cell disease fight.
Unlocked Potential — ‘Keying’ in On New-Era Engagement
September 11, 2020
How adoption of the key account management (KAM) model can help drive pharma’s agility in reaching and influencing a more diverse set of healthcare customers and decision-makers.
Commercializing an Orphan Drug: Why “Just” Serving a High Unmet Medical Need Won’t Do the Job
September 08, 2020
Looking at four building blocks of success, Wolfram Lux and Simone Seiter investigate what it takes to win and be successful when commercializing an orphan drug
Don’t Waste A Crisis: How Paratek is Navigating the Business Implications of the COVID-19 Pandemic
August 31, 2020
A look at how pharmaceutical company, Paratek is navigating the launch of a new antibiotic during the COVID-19 pandemic.
How Pharma Reps and Managers Can Work to Overcome the In-Person HCP Barrier
August 19, 2020
While HCPs are turning away from in-person meetings with sales reps amidst the COVID-19 pandemic, there are still strategies for them to keep their pipelines full.
The Impact of Accelerated Drug Development
August 18, 2020
Dr. Manuel Hermosilla shares his thoughts on how the pharmaceutical industry reacts to challenges that arise during trials, specifically during the search for an effective COVID-19 vaccine.
Tapping Compliance Data to Drive Success
August 10, 2020
How pharma leaders can convert data collected for compliance purposes from a cost center into a critical success factor.
Strategic Realignment for a Better Future
July 21, 2020
In adjusting to the long-term side-effects of the coronavirus pandemic, pharma companies will need to focus on change in three areas. Ben van der Schaaf and Aurelien Guichard report.